Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Change in Receivables for 6 consecutive years, with $266000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables rose 103.26% year-over-year to $266000.0; the trailing twelve-month figure through Jun 2026 stood at -$8.4 million (down 173.48% YoY), and the FY2025 full-year result was -$26.1 million, down 227.73% from the prior year.
• Change in Receivables fell to $266000.0 in Q2 2026 per KNSA's latest filing, from $7.6 million in the prior quarter.
• Across five years, Change in Receivables topped out at $25.5 million in Q1 2022 and bottomed at -$36.1 million in Q4 2025.
• Historically, Change in Receivables has averaged $1.1 million across 5 years, with a median of $2.4 million in 2022.
• The widest YoY moves for Change in Receivables: up 1114.19% in 2023, down 744.85% in 2023.
• Over 5 years, Change in Receivables stood at $1.5 million in 2022, then soared by 1114.19% to $18.2 million in 2023, then retreated by 7.62% to $16.8 million in 2024, then slumped by 314.71% to -$36.1 million in 2025, then soared by 100.74% to $266000.0 in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $266000.0, $7.6 million, and -$36.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.